Antihemophilic Factor (Recombinant), Porcine Sequence (Obizur)
Antihemophilic Factor (Recombinant), Porcine Sequence is an FDA-licensed reference biologic from Takeda Pharmaceuticals U.S.A., Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2014
Reference approved
Reference product
Obizur Antihemophilic Factor (Recombinant), Porcine Sequence
Takeda Pharmaceuticals U.S.A., Inc.
- Approved
- Oct 23, 2014
- Marketing
- Rx
- Center
- CBER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for Antihemophilic Factor (Recombinant), Porcine Sequence, in chronological order.
Reference approval
Approval date of the reference Antihemophilic Factor (Recombinant), Porcine Sequence product.
11 yr 9 mo ago
Orphan exclusivity ends
7-year orphan-drug exclusivity window.
4 yr 8 mo ago
Frequently asked questions
Are there biosimilars approved for Antihemophilic Factor (Recombinant), Porcine Sequence (Obizur)?
No 351(k) biosimilars or interchangeable biosimilars referencing Antihemophilic Factor (Recombinant), Porcine Sequence are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.